The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Liver metastases as predictors of outcome in renal cell carcinoma (RCC) patients (pts) treated with first-line sunitinib (SU) and sorafenib (SO).
Paolo Grassi
No relevant relationships to disclose
Elena Verzoni
No relevant relationships to disclose
Luca Porcu
No relevant relationships to disclose
Isabella Testa
No relevant relationships to disclose
Roberto Iacovelli
No relevant relationships to disclose
Enrico Garanzini
No relevant relationships to disclose
Roberto Salvioni
No relevant relationships to disclose
Filippo G. De Braud
No relevant relationships to disclose
Giuseppe Procopio
Employment or Leadership Position - Astellas Pharma; Bayer; GlaxoSmithKline
Consultant or Advisory Role - Janssen; Novartis; Pfizer; Sanofi